Stock Pulse
Abbott Laboratories (ABT) is expected to announce Q1 2025 earnings on April 16th, with projected EPS of $1.07 (+9.2% YoY) and revenue of $10.42 billion (+4.5% YoY) [1], [4], [6], [10]. Growth is anticipated across most segments, particularly Medical Devices (Diabetes Care and Structural Heart) [1], [4], while Diagnostics may slightly decline [1]. Increased competition from Dexcom's newly approved diabetes device poses a potential risk to Abbott's market share in this segment [5]. Despite a recent 2% stock decline [6] and decreased institutional holdings [7], analysts maintain a positive outlook, with upward revisions to EPS estimates and a Zacks Rank #2 (Buy), suggesting potential market outperformance [1], [6], [10]. Abbott has a history of exceeding earnings expectations [10], and its strong pipeline and diversified product portfolio are viewed as strengths [2].